Aether Industries Limited — Cyborg Score 8/10

Strong
Specialty Chemicals Manufacturing & CRAMS

Strategic Profile

The company operates through three business segments: Large Scale Manufacturing (59%), Contract Manufacturing (26%), and CRAMS (14%). Aether began operations at Manufacturing Site 3 in Gujarat on February 22, 2026, expected to enhance production and revenue. The company targets 70% revenue from CRAMS and CEM in the future.

Cyborg Score Rationale

Q3 FY26 reported 44% YoY revenue growth to INR 3,171M, with EBITDA up 75% and PAT increasing 49%. The company is almost debt free. Guides sustainable EBITDA margin of 29-30% post Q3 FY2026.

Top Insights

  • Q3 FY26 showed exceptional growth: 44% YoY revenue rise, 75% EBITDA growth, 49% PAT increase
  • US tariff reduction from 50% to 18% under 2026 trade deal boosts Indian chemical exports; Aether positioned as a beneficiary
  • Aether is sole manufacturer in India of 4MEP, MMBC, T2E, OTBN, NODG, DVL and Bifenthrin Alcohol; largest global manufacturer by volume for 4MEP, T2E, NODG, and HEEP
  • Company added 5 marquee clients and introduced 3 new products; targets 70% revenue from high-margin CRAMS/CEM segments

Named Competitors

  • Specialty Chemicals — Indian specialty chemical manufacturer competing in pharmaceutical and agro-chemical intermediates
  • Specialty Chemicals & CRAMS — Contract research and manufacturing services provider in specialty chemicals

Recent Developments

  • (February 2026) Manufacturing Site 3 operations commenced in Gujarat
  • (February 2026) Q3 FY26 results: 44% YoY revenue growth, strong profit expansion across metrics
  • (January 2026) Share price gained 32.62% over past 6 months, demonstrating market confidence

Open the full interactive Aether Industries Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →